|
|
|
과민성방광 환자에서 이미다페나신 0.2mg 복용으로 인한 증상 호전의 예측인자 |
| 부산대학교 의과대학/의학전문대학원 비뇨의학교실 |
| 김현우, 백승룡, 김경환, 박지훈, 강병진, 박시균, 신동길, 이정주 |
Objective: To investigate the predicting factors for symptom improvement in overactive bladder (OAB) patients who are treated with Imidafenacin 0.2mg.
Methods: The study included 66 females with OAB who were prescribed with Imidafenacin 0.2mg/day for at least 3 months. Clinical data including OAB symptom score questionnaire (OABSS) which was answered before and 3 months after Imidafenacin medication were investigated. The OAB severity was classified according to total OABSS as follows: ≤ 5 as mild, ≥ 6 and ≤ 11 as moderate, and ≥12 as severe. Total OABSS and OAB severity were used to evaluate the efficacy of 3 months Imidafenacin medication. The patients were sorted into two groups (Group A: patients with no improvement in OAB severity; and Group B: patients with improved OAB severity) and logistic regression test was performed to analyze the predicting factors for OAB symptom improvement by Imidafenacin.
Results: The mean values of total OABSS before and 3 months after Imidafenacin medication were 8.36 ± 3.65 and 5.15 ± 3.22, respectively. The total OABSS and OAB severity were significantly improved after the 3 months of medication (p 〈0.001 for both). The comparison data of Groups A and B are shown in Table 1. Multivariable analysis showed OABSS subscore of item 1 and 3 before the medication were the significant factors that can predict the improvement of OAB severity after Imidafenacin medication (Table 2).
Conclusions: Imidafenacin can improve OAB severity in females, and OABSS subscore of item 1 and 3 before initiating the drug may predict the effectiveness. |
  |
|
keywords : imidafenacin, prediction, overactive bladder |
|
